Endurance (Cayman) Ltd Svf Sells 72,133 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Key Points

• Endurance (Cayman) Ltd Svf sold a total of 72,133 shares of Vir Biotechnology at an average price of $5.60, reducing its ownership by 0.45% to approximately 16,087,611 shares.
• Vir Biotechnology's stock is currently trading at $6.04 after a 0.2% decline, and the company reported a significant 60.5% decline in quarterly revenue compared to the same period last year.
• Analysts have mixed views on Vir Biotechnology, with recent upgrades and target price increases, including a buy rating from Bank of America and a target price of $14.00.

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) major shareholder Endurance (Cayman) Ltd Svf sold 72,133 shares of Vir Biotechnology stock in a transaction that occurred on Tuesday, October 7th. The stock was sold at an average price of $5.60, for a total value of $403,944.80. Following the completion of the transaction, the insider directly owned 16,087,611 shares in the company, valued at approximately $90,090,621.60. This represents a 0.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Endurance (Cayman) Ltd Svf also recently made the following trade(s):

• On Wednesday, October 8th, Endurance (Cayman) Ltd Svf sold 466,242 shares of Vir Biotechnology stock. The shares were sold at an average price of $6.05, for a total value of $2,820,764.10.
• On Monday, October 6th, Endurance (Cayman) Ltd Svf sold 73,955 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.69, for a total value of $420,803.95.
• On Friday, October 3rd, Endurance (Cayman) Ltd Svf sold 450,342 shares of Vir Biotechnology stock. The shares were sold at an average price of $5.56, for a total value of $2,503,901.52.

Vir Biotechnology Stock Down 0.2%

VIR traded down $0.01 during trading on Thursday, hitting $6.04. The company's stock had a trading volume of 2,398,952 shares, compared to its average volume of 1,554,745. Vir Biotechnology, Inc. has a twelve month low of $4.16 and a twelve month high of $14.45. The stock's fifty day moving average price is $5.02 and its 200-day moving average price is $5.32. The firm has a market capitalization of $839.08 million, a P/E ratio of -1.51 and a beta of 1.27.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $2.38 million. During the same period last year, the firm posted ($1.02) earnings per share. Vir Biotechnology's quarterly revenue was down 60.5% compared to the same quarter last year. Equities research analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

VIR has been the topic of a number of research reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Vir Biotechnology in a research report on Saturday, September 27th. Raymond James Financial initiated coverage on Vir Biotechnology in a research report on Friday, July 11th. They set an "outperform" rating on the stock. HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Vir Biotechnology in a research report on Monday, September 15th. Bank of America raised Vir Biotechnology from a "neutral" rating to a "buy" rating and upped their target price for the stock from $12.00 to $14.00 in a research report on Wednesday, August 27th. Finally, Evercore ISI began coverage on Vir Biotechnology in a research report on Wednesday, September 3rd. They set an "outperform" rating and a $12.00 target price on the stock. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.30.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC bought a new position in Vir Biotechnology in the 1st quarter valued at $78,000. Cinctive Capital Management LP bought a new position in Vir Biotechnology in the 1st quarter valued at $547,000. Goldman Sachs Group Inc. grew its stake in Vir Biotechnology by 43.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company's stock valued at $4,813,000 after purchasing an additional 225,544 shares during the period. GAMMA Investing LLC grew its stake in Vir Biotechnology by 524.3% in the 1st quarter. GAMMA Investing LLC now owns 7,111 shares of the company's stock valued at $46,000 after purchasing an additional 5,972 shares during the period. Finally, Nuveen LLC bought a new position in Vir Biotechnology in the 1st quarter valued at $2,324,000. Institutional investors own 65.32% of the company's stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.